Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma.
Hu Y, Liu H, Fang C, Li C, Xhyliu F, Dysert H, Bodo J, Habermehl G, Russell BE, Li W, Chappell M, Jiang X, Ondrejka SL, Hsi ED, Maciejewski JP, Yi Q, Anderson KC, Munshi NC, Ao G, Valent JN, Lin J, Zhao J
Cancer Res. 2020 Mar 19. pii: 0008-5472.CAN-19-1077. doi: 10.1158/0008-5472.CAN-19-1077. PubMed Article
Hu Y, Liu H, Fang C, Li C, Xhyliu F, Dysert H, Bodo J, Habermehl G, Russell BE, Li W, Chappell M, Jiang X, Ondrejka SL, Hsi ED, Maciejewski JP, Yi Q, Anderson KC, Munshi NC, Ao G, Valent JN, Lin J, Zhao J
Cancer Res. 2020 Mar 19. pii: 0008-5472.CAN-19-1077. doi: 10.1158/0008-5472.CAN-19-1077. PubMed Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 134936 | pCDH-MSCV-hCD38-EF1α-GFP+Puro | expression human CD38 in mammalian cells |